In premenopausal patients with early breast cancer, triptorelin plus tamoxifen and FEC50 had similar disease-free survival, including multivariate analysis.
In plain wordsIn premenopausal breast cancer patients, disease-free survival was similar with triptorelin plus tamoxifen and FEC50 chemotherapy.
- Outcome
- No significant changeDisease-free survival
- Study
n = 333
- Comparator
- FEC50 chemotherapy
- Outcome group
- Tumor growth · Cancer
Measurements
- 7-year disease-free survival
- 76%
- triptorelin plus tamoxifen
- 7-year disease-free survival
- 72%
- FEC50
Source sentences
The 7-year disease-free survival (DFS) was 76% with TAM-LHRHa, and 72% with FEC50 (P=0.13).
3 context sentences(design, population, supporting numbers)
The multivariate analysis confirmed that both treatments were not different for DFS and OS (P=0.83 and P=0.41, respectively).
The purpose of this study was to determine optimal adjuvant therapy between complete hormonal blockade in premenopausal patients with hormone receptor positive breast cancer and one to three positive nodes.
We randomised 333 patients to receive either LHRH agonist (triptorelin 3.75 mg i.m., monthly) plus tamoxifen 30 mg/day for 3 years (TAM-LHRHa, n=164), or fluorouracil 500 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 21 days for six cycles, without any hormonal treatment (FEC50, n=169).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).